Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended			3 Months Ended
	Nov. 30, 2017 USD ($)	Oct. 31, 2017	Oct. 31, 2016 USD ($)	Mar. 31, 2018 USD ($) Milestone
UFRF License Agreement [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product				5.00%
Company's obligation to pay from all revenue received from sublicenses				22.00%
One-time commercialization fee monthly amount for calculation				$ 5,000
Post-commercialization minimum royalty payments				50,000
One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount				$ 2,000,000
One-time additional payment to UFRF as a percentage of total royalties due to UFRF				10.00%
Minimum annual maintenance payment on license agreement				$ 10,000
Quarterly maintenance payment to UFRF under installment plan				$ 2,500
Termination notice period				90 days
Texas A and M University License [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product				5.00%
Post-commercialization minimum royalty payments				$ 100,000
Initial payment to Texas A&M				5,000
Minimum consideration for the continuation of the license agreement				$ 15,000
Number of milestones achieved \| Milestone				0
Texas A and M University License [Member] \| Amendment [Member]
Commitment And Contingencies [Line Items]
Minimum consideration for the continuation of the license agreement			$ 25,000
Texas A and M University License [Member] \| Phase 1 Clinical Trial [Member]
Commitment And Contingencies [Line Items]
Date of milestone achievement under licensing agreement with Texas A&M				Jun. 01, 2019
Milestone payment under licensing agreement				$ 50,000
Texas A and M University License [Member] \| Phase 2 Clinical Trial [Member]
Commitment And Contingencies [Line Items]
Date of milestone achievement under licensing agreement with Texas A&M				Jun. 01, 2022
Milestone payment under licensing agreement				$ 100,000
Texas A and M University License [Member] \| Phase 3 Clinical Trial [Member]
Commitment And Contingencies [Line Items]
Date of milestone achievement under licensing agreement with Texas A&M				Jun. 01, 2025
Milestone payment under licensing agreement				$ 150,000
Texas A and M University License [Member] \| Sale Of Licensed Technology [Member]
Commitment And Contingencies [Line Items]
Date of milestone achievement under licensing agreement with Texas A&M				Jun. 01, 2026
Milestone payment under licensing agreement				$ 400,000
Texas A and M University License [Member] \| Minimum [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product				2.00%
Lantibiotic ECC [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product				10.00%
Company's obligation to pay from all revenue received from sublicenses	25.00%			25.00%
Number of milestones achieved \| Milestone				0
Royalty rate based on percentage of net sales	10.00%
Lantibiotic ECC [Member] \| Scenario, Previously Reported [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from all revenue received from sublicenses		50.00%
Royalty rate based on percentage of product profit		25.00%
Lantibiotic ECC [Member] \| Regulatory Approval Application Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 25,000,000
Milestone measurement period				6 months
Lantibiotic ECC [Member] \| New Indication Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 5,000,000
Milestone measurement period				6 months
Lantibiotic ECC [Member] \| New Product Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 5,000,000
Milestone measurement period				6 months
Lantibiotic ECC [Member] \| New Drug Application [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement	$ 25,000,000
Milestone measurement period	6 months
Lantibiotic ECC [Member] \| Minimum [Member]
Commitment And Contingencies [Line Items]
Advancement expended amount for lantibiotic program	$ 1,200,000
Oral Mucositis ECC [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product				12.00%
Company's obligation to pay from all revenue received from sublicenses	25.00%			25.00%
Number of milestones achieved \| Milestone				0
Oral Mucositis ECC [Member] \| Scenario, Previously Reported [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from all revenue received from sublicenses		50.00%
Oral Mucositis ECC [Member] \| Regulatory Approval Application Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 27,500,000
Milestone measurement period				6 months
Oral Mucositis ECC [Member] \| New Indication Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 5,000,000
Milestone measurement period				6 months
Oral Mucositis ECC [Member] \| New Product Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 5,000,000
Milestone measurement period				6 months
Oral Mucositis ECC [Member] \| New Product Application [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement	$ 27,500,000
Milestone measurement period	6 months
Oral Mucositis ECC [Member] \| Maximum [Member]
Commitment And Contingencies [Line Items]
Maturity of interest bearing promissory note				12 months